JANUARY 2007
- Allergan announced nationwide availability of JUVÉDERM™ Ultra and JUVÉDERM™ Ultra Plus, its next-generation hyaluronic acid dermal filler family of products.
- Allergan acquired Groupe Cornéal Laboratories, obtaining exclusive rights to market and manufacture JUVÉDERM™.
- Allergan launched OPTIVE™ Lubricant Eye Drops, a next-generation artificial tear to provide long-lasting relief from dry eye symptoms, to U.S. eye care professionals.
- Institutional Investor magazine — David Pyott named one of the “Top CEOs in America.”
FEBRUARY 2007
- Allergan acquired Swiss company EndoArt SA, a leader in the field of telemetrically-adjustable gastric banding devices for the treatment of morbid obesity.
- Pharmafocus — Allergan voted the “Rising Star of Specialist Pharma with a U.K. presence.”
MARCH 2007
- Allergan launched the VIVITÉ® skin care line, which includes proprietary GLX Technology™ and is clinically shown to help reduce the appearance of fine lines and wrinkles, in the United States.
APRIL 2007
- Allergan launched The NATRELLE™ Collection of saline-filled and silicone gel-filled breast implants.
- Allergan celebrated the fifth anniversary of the U.S. Food and Drug Administration’s (FDA) approval of BOTOX® Cosmetic (botulinum toxin type A) for the temporary treatment of moderate to severe glabellar lines between the brows (the vertical frown lines between the eyebrows that look like an “11”) in people ages 18–65.
- Allergan opened a state-of-the-art manufacturing plant in Costa Rica, to supply breast aesthetics and obesity intervention devices worldwide.
JUNE 2007
- Allergan announced approval by the FDA of label extensions for JUVÉDERM™ Ultra and JUVÉDERM™ Ultra Plus based on new clinical data demonstrating that the effects of both products may last for up to one year.
AUGUST 2007
- Allergan announced the opening of the Allergan Pharmaceutical Development Center in Bangalore, India, to implement global pharmaceutical research and development projects that Allergan conducts in India. The Center will initially focus on the development of new intraocular pressure-lowering compounds.
SEPTEMBER 2007
- Med Ad News published its list of the top 50 health care companies. Allergan ranked: number 34 by health care revenue, number 22 by research and development expenditure, number 34 by consolidated revenue and number 34 by shareholders’ equity.
OCTOBER 2007
- Allergan received FDA approval of COMBIGAN™ for the reduction of elevated intraocular pressure (IOP) in patients with glaucoma or ocular hypertension who require adjunctive therapy or replacement therapy due to inadequately controlled IOP.
- Allergan acquired Esprit Pharma, Inc., a U.S.-based pharmaceutical company with expertise in the genitourinary market and treatments for overactive bladder, including SANCTURA XR™ (trospium chloride extended release capsules). With this acquisition, Allergan entered the genitourinary specialty and created a dedicated Urologics division.
NOVEMBER 2007
- Allergan entered into a co-promotion agreement in the United States with Covidien Ltd., a leading global provider of health care products, to deepen Allergan’s reach into the bariatric community with additional sales force and other specialized staff support to further promote, educate and train surgeons on the LAP-BAND® Adjustable Gastric Banding System.
- For the twelfth consecutive year, Allergan received a Waste Reduction Award from the California Integrated Waste Management Board. In 2006, Allergan recycled approximately 2,850 tons of materials and had a recycling rate of approximately 60 percent worldwide.
- Allergan entered into a strategic collaboration with Stiefel Laboratories, Inc., a pharmaceutical company specializing in dermatology, to further strengthen Allergan’s presence in the medical dermatology market and to develop and market new products using Allergan’s proprietary tazarotene compound.
DECEMBER 2007
- MSNBC.com — Allergan named among “348 Incredible Companies” based upon strong stock market performance among mid- to large-cap companies over the past 10 years.
- Forbes magazine — Allergan featured among “America’s Best-Managed Companies.”
JANUARY 2008
- Allergan launched SANCTURA XR™, a once-daily medication for the treatment of overactive bladder with symptoms of urge urinary incontinence, urgency and urinary frequency, in the United States.
- The Wall Street Journal listed Allergan at number 11 among the top 35 companies by their Patent Board science strength ranking, and number 11 among the top 30 pharmaceutical companies by stock market performance data for the past 52 weeks.
- The Globe and Mail — Allergan Canada ranked number 16 among “The 25 Best Small Companies To Work For.”
MARCH 2008
- The U.S. Environmental Protection Agency recognized Allergan for its commitment and dedication to energy efficiency as a 2008 ENERGY STAR award winner for “Partner of the Year – Energy Management.”